Schubert & Co’s Intellia Therapeutics NTLA Stock Holding History

Schubert & Co’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1	Closed	–	–	1249
2021 Q4	$0	Buy	+1	New	+$125	﹤0.01%	1194

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Schubert & Co's NTLA Position: Q1 2022 in Review

Schubert & Co sold out of Intellia Therapeutics (NTLA) in Q1 2022, closing a stake of 1 share.

Schubert & Co first reported a position in NTLA in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 348 funds tracked by Wall St. Rank hold NTLA as of Q1 2022.

Schubert & Co reported no remaining Intellia Therapeutics position as of Q1 2022 after selling out during the quarter.
Schubert & Co sold 1 Intellia Therapeutics share in Q1 2022.
Schubert & Co first reported a position in Intellia Therapeutics in Q4 2021 and held it in 1 quarter.
Schubert & Co's Intellia Therapeutics position peaked at $0 in Q4 2021.
348 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2022.

Based on Schubert & Co's 13F filing for Q1 2022, filed 16 May 2022.